Source: Annual Congress 2011 - Clinical features of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Mathai, K. Kroening, L. Hummers, A. Zaiman, R. Girgis, P. Hassoun (Baltimore, United States Of America). Differences between limited and diffuse systemic sclerosis-related pulmonary arterial hypertension. Eur Respir J 2011; 38: Suppl. 55, 2331

Member's Comments

No comment yet.

Related content which might interest you: Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension Source: Eur Respir J 2010; 35: 6-8 Year: 2010 Vasodilator testing in pulmonary arterial hypertension associated with systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006 Identifying early pulmonary arterial hypertension in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1800495; 10.1183/13993003.00495-2018 Year: 2018 Gas transfer relates to pulmonary haemodynamics and survival in pulmonary arterial hypertension associated with systemic sclerosis Source: Eur Respir J 2007; 30: Suppl. 51, 344s Year: 2007 Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy Source: Eur Respir J 2009; 33: 371-379 Year: 2009 Pulmonary hypertension and arterial stiffness in patients with systemic scleroderma Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Screening for pulmonary arterial hypertension in systemic sclerosis Source: Eur Respir Rev 2009; 18: 162-169 Year: 2009 Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension Source: Eur Respir J, 52 (4) 1800678; 10.1183/13993003.00678-2018 Year: 2018 Ventricular mass index correlates with pulmonary haemodynamics in patients with systemic sclerosis and suspected pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Systemic consequences of pulmonary arterial hypertension Source: International Congress 2019 – State of the art session: Pulmonary vascular diseases Year: 2019 Pulmonary arterial hypertension in scleroderma – manifestation of systemic endothelial dysfunction Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006 Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening Source: Eur Respir Rev 2011; 20: 270-276 Year: 2011 Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension Source: Eur Respir J, 52 (4) 1801745; 10.1183/13993003.01745-2018 Year: 2018 Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA Source: ERJ Open Res, 6 (2) 00309-2019; 10.1183/23120541.00309-2019 Year: 2020 Predictors of pulmonary artery hypertension in patients with systemic sclerosis Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach Year: 2012 Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Prevalence of pulmonary hypertension in limited and diffuse scleroderma Source: Eur Respir J 2003; 22: Suppl. 45, 465s Year: 2003 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Patterns of mean pulmonary artery pressure (mPAP)-flow relation changes following chronic therapy in idiopathic pulmonary arterial hypertension (IPAH) Source: Eur Respir J 2006; 28: Suppl. 50, 427s Year: 2006 Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011